N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Jiahe Yi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Center, Zhejiang University, Ha…. Hauptthemen laut MEDLINE: MicroRNAs, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Several studies have indicated that circular RNAs (circRNAs) play vital roles in the progression of various diseases, including bladder cancer (BCa). However, the underlying mechanisms by which circRNAs drive BCa malignancy remain unclear. In this study, we identified a novel circRNA, circPSMA7 (circbaseID:has_circ_0003456), showing increased expression in BCa cell lines and tissues, by integrating the reported information with circRNA-seq and qRT-PCR. We revealed that circPSMA7 is associated with a higher tumor grade and stage in BCa. M6A modification was identified in circPSMA7, and IGF2BP3 recognized this modification and stabilized circPSMA7, subsequently increasing the circPSMA7 expression. In vitro and in vivo experiments showed that circPSMA7 promoted BCa proliferation and metastasis by regulating the cell cycle and EMT processes. CircPSMA7 acted as a sponge for miR-128-3p, which showed antitumor effects in BCa cell lines, increasing the expression of MAPK1. The tumor proliferation and metastasis suppression induced by silencing circPSMA7 could be partly reversed by miR-128-3p inhibition. Thus, the METTL3/IGF2BP3/circPSMA7/miR-128-3p/MAPK1 axis plays a critical role in BCa progression. Furthermore, circPSMA7 may be a potential diagnostic biomarker and novel therapeutic target for patients with BCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Center, Zhejiang University, Hangzhou, 310058 China.
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Center, Zhejiang University, Hangzhou, 310058 China. Electronic address: zjulyw@zju.edu.cn.
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Center, Zhejiang University, Hangzhou, 310058 China. Electronic address: lijf@zju.edu.cn.
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Center, Zhejiang University, Hangzhou, 310058 China. Electronic address: xielp@zju.edu.cn.
Zitieren
APA
Yi, J., Ma, X., Ying, Y., Liu, Z., Tang, Y., Shu, X., Sun, J., Wu, Y., Lu, D., Wang, X., Luo, J., Liu, B., Zheng, X., Lin, Y., Li, J., & Xie, L. (2024). N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216613
Vancouver
Yi J, Ma X, Ying Y, Liu Z, Tang Y, Shu X, et al. N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216613
BibTeX
@article{Yi2024,
author = {Yi, Jiahe and Ma, Xueyou and Ying, Yufan and Liu, Zixiang and Tang, Yijie and Shu, Xuan and Sun, Jiazhu and Wu, Yuqing and Lu, Dingheng and Wang, Xiao and Luo, Jindan and Liu, Ben and Zheng, Xiangyi and Lin, Yiwei and Li, Jiangfeng and Xie, Liping},
title = {N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216613}
}
EUVIMED